Kornimate/medical-research-clean huggingface dataset:
thoracic manipulation versus myofascial release in patients with shoulder impingement syndrome

Conditions: Impingement Shoulder

Summary: aims: • to investigate the effect of adding thoracic manipulation vs myofascial release to scapular stabilization exercise on pain intensity. * to investigate the effect of adding thoracic manipulation vs myofascial release to scapular stabilization exercise on pain pressure threshold. * to investigate the effect of adding thoracic manipulation vs myofascial release to scapular stabilization exercise on shoulder proprioception. * to investigate the effect of adding thoracic manipulation vs myofascial release to scapular stabilization exercise on shoulder range of motion(rom). * to investigate the effect of adding thoracic manipulation vs myofascial release to scapular stabilization exercise on disability of shoulder and hand questionnaire(dash).

various researches have been done on rehabilitation of shoulder impingement by addressing either osseous structure or myofascial structure and found to be effective. but no studies could retrieve to compare these two: myofascial release and thoracic manipulation. (dash \& deepak, 2020). so in this study we will investigate the effect of adding thoracic manipulation versus myofascial release in patients with shoulder impingement syndrome. we will investigate the effect on each of the following: pain intensity will measure by visual analogue scale.(vas). proprioception of the shoulder by isokinetic dynamometer. pain pressure threshold by algometer. function by dash questionnaire and finally rom by kinovea software. the subjects will be arranged into three groups: group i (control group) will receive scapular stabilization exercises. * group ii will receive scapular stabilization exercises and thoracic manipulation combined with shoulder mobilization. * group iii will receive scapular stabilization exercises and myofascial release by instrument assisted soft tissue mobilization techniques(iastm). the measurements will take before and after treatment programs and after one month of follow up.

Eligibility criteria:
inclusion criteria: 1. sixty patients with shoulder impingement syndrome from both genders their age will be ranged and divided into three groups from 25-40 years. 2. history of shoulder pain for at least one month. 3. positive neer's impingement test and hawkins's kiennedy test. 4. presence of thoracic hypomobility from clinical evaluation. 5. provocation of pain above 60 degrees of flexion and abduction. 6. palpable trigger points on shoulder muscles. exclusion criteria: 1. history of shoulder girdle fracture, dislocation and surgery 2. diagnosed with frozen shoulder or rotator cuff tear 3. history of cervicobrachial pain 4. any neuromuscular pain in upper limb and use of corticosteroids or pain subsiding medication
conversion study from epoetin alfa to monthly peginesatide injection in patients with chronic kidney disease on dialysis

Conditions: Chronic Kidney Disease; Anemia

Summary: the purpose of this study is to understand the effects of a dialysis center switching its dialysis patients from using epoetin alfa to peginesatide injection on hemoglobin levels and other parameters.

monthly erythropoiesis-stimulating agents (esa) dosing, compared with the longstanding practice of dosing three times per week, represents a significant change in anemia treatment for dialysis patients. because of the differences in the processes needed to support monthly dosing versus thrice weekly dosing, there is a need to prospectively identify and evaluate factors in the dialysis environment during center-level transition of patients from one esa to another. afx01-18 is a phase 3b open-label, single-arm conversion study that was conducted at 5 hemodialysis sites in the united states, and enrolled chronic kidney disease (ckd) patients receiving outpatient, in-center hemodialysis. the study treatment period was approximately 12 months in duration. participants received peginesatide injection for approximately six months.

Eligibility criteria:
inclusion criteria: * have provided written informed consent in accordance with institutional, local, and national guidelines * are ≥18 years of age at the start of screening * have been on in-center hemodialysis for ≥12 weeks at the start of screening * are currently maintained on epoetin at the start of screening * if sexually active and a female of childbearing potential, are willing to use highly effective method of birth control ≥4 weeks before study enrollment and through the study * if a female of childbearing potential, have a negative pregnancy test during screening exclusion criteria: * are scheduled for a renal transplantation during study (note: patients awaiting transplantation with no date scheduled may enroll.) * have an active malignancy or malignancy treated within one year prior to the start of screening for curative or palliative intent (note: patients with non-melanoma skin cancers may enroll.) * have known intolerance to any esa or pegylated molecule * have been exposed to any investigational agent during the four weeks prior to the start of screening or are anticipated to receive such agents during the study * have any significant medical or psychiatric condition judged by the investigator to prevent informed consent or study compliance * are pregnant or nursing

Keywords: anemia chronic renal failure crf chronic kidney disease ckd erythropoietin hematide peginesatide hemoglobin hgb red blood cell red blood cell production dialysis
a single-patient study of repeat-dose administration of prometic plasminogen (human) intravenous

Conditions: Hypoplasminogenemia

Summary: these are single-patient studies with repeat-dose administration of prometic plasminogen iv infusion in one adult and one child with hypoplasminogenemia. these patients are under treatment to address wound healing and obstructions.


Eligibility criteria:
inclusion criteria: * patient has provided informed consent. * patient has a diagnosis of compound homozygous type 1 plasminogen deficiency as evidence by ligneous conjunctivitis since birth as well as involvement of the conjunctiva, nasopharynx, gingiva, tracheobronchial tree, gastrointestinal tract, and urinary tract. exclusion criteria: * not applicable
clinical and structural outcome of conventional versus accelerated corneal collagen cross-linking (cxl).

Conditions: Keratoconus; Corneal Ectasia

Summary: compare different corneal parameters and visual outcome of corneal collagen cross-linking (cxl) with conventional versus accelerated ultraviolet-a irradiation using riboflavin with hydroxypropyl methylcellulose.

40 patients with signs of progressive keratoconus are randomized to either corneal collagen cross-linking (cxl) with conventional ultraviolet-a (uva) irradiation at 3 milliwatt/cm² (mw/ cm²) or accelerated ultraviolet-a (uva) irradiation at 9 mw/ cm². in both groups riboflavin with hydroxypropyl methylcellulose was used. the objectives of this study are to evaluate and compare different corneal parameters (maximum corneal curvature, depth of collagen cross-linking, endothelial cell density) and clinical outcomes of uncorrected visual acuity (ucva) and best spectacle corrected visual acuity (bscva)) after cxl with conventional and accelerated uva irradiation.

Eligibility criteria:
inclusion criteria: * patients with increase of minimum of 1,0 diopter in maximum keratometry. * patients with increase in corneal astigmatism of minimum 1,0 diopter. * patients with in spherical equivalent of min 0,5 diopter. * patients living in eastern norway. exclusion criteria: * minimum pachymetric corneal thickness (pentacam)\<360 µm. * central corneal scar. * chemical burn, serious corneal infections and ocular surface diseases. * pregnancy. * lactation.
fentanyl sublingual spray for the treatment of moderate to severe post-operative pain

Conditions: Pain

Summary: the primary objective of this trial is to evaluate analgesic efficacy of fentanyl sublingual spray compared with placebo in participants with postoperative pain after a bunionectomy.


Eligibility criteria:
inclusion criteria: * meets protocol-specified criteria for qualification and contraception * willing and able to remain confined in the study unit for the entire duration of each treatment period and comply with restrictions related to food, drink and medications * voluntarily consents to participate and provides written informed consent prior to any protocol-specific procedures exclusion criteria: * history or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters * signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1. the safety or well-being of the participant or study staff; 2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding); 3. the analysis of results
a study of avastin (bevacizumab) in combination chemotherapy in patients with metastatic cancer of the colon or rectum

Conditions: Colorectal Cancer

Summary: a study of avastin (bevacizumab) in combination chemotherapy in patients with metastatic cancer of the colon or rectum. the anticipated time on study treatment is until disease progression.


Eligibility criteria:
inclusion criteria: * adult patients \>=18 years of age; * colon or rectal cancer, with metastases; * \>=1 measurable lesion. exclusion criteria: * previous systemic treatment for advanced disease; * radiotherapy to any site within 4 weeks before study; * daily aspirin (\>325 mg/day), anticoagulants, or other medications known to predispose to gastrointestinal ulceration; * co-existing malignancies or malignancies diagnosed within last 5 years (except basal cell cancer or cervical cancer in situ).
a digital intervention to improve physical activity and sleep behaviors in youth with psychiatric diagnoses

Conditions: Psychiatric Diagnosis

Summary: the goal of "gamerfit" is to test the delivery of a theory-based mhealth app that utilizes social support, exergaming, and telehealth coaching to improve pa levels, sleep, and psychiatric symptoms among youth participants (ages 13-17 y) with pd. in order to aid future intervention optimization, up to 65 participants with at least one pd will be randomized, with 30-35 using the gamerfit app with weekly telehealth coaching sessions and 30-35 using a commercial healthy habits app as a comparator group


Eligibility criteria:
inclusion criteria: * 13-17 years of age (child/participant) * at least one pd diagnosis (excluding eating disorders) confirmed by parent report of physician diagnosis (child/participant) * iq≥85/no intellectual disability that precludes participation confirmed by parent report (child/participant) * can understand verbal english-language exergaming instructions (child/participant) * physically capable of exercise confirmed by parent report (child/participant) * has access to a smart phone or compatible tablet (child/participant) * willing to download and use the app (child/participant) * willing and able to be present during telehealth coaching sessions (parent) * can have a competent translator present during coaching sessions if not fluent in english (parent) exclusion criteria: - families for whom the mpis think the study and/or intervention is clinically/medically inappropriate (e.g. developmental delay, or emotional or cognitive difficulties, if the pi believes these factors will interfere with study/intervention participation)
gastric swab for helicobacter pylori detection

Conditions: Helicobacter Pylori Infection

Summary: a randomized controlled trial for comparing the helicobacter pylori test using the swap method and the method using the conventional biopsy.

the aim of this study is to conduct a prospective study under the hypothesis that a cotton swab method in the rapid urease test is not inferior to the conventional biopsy.

Eligibility criteria:
inclusion criteria: * adults aged 20-80 * patients who undergo esophagogastroduodenoscopy and need for investigation of helicobacter pylori infection. exclusion criteria: * surgical history of any kind of gastrectomy * patients with contraindication of esophagogastroduodenoscopy

Keywords: helicobacter pylori rapid urease test swab
validation of an algorithm for the diagnosis of sarcopenic obesity

Conditions: Sarcopenic Obesity

Summary: the proposed research project aims to investigate sarcopenic obesity (so), a condition characterized by the combination of high body fat and low skeletal muscle mass, with a focus on muscle function. so has been defined according to the espen-easo algorithm, and this study aims to evaluate its validity, exploring associations with circulating biomarkers and functional outcomes. by enrolling 75 subjects with so and a control sample of 75 subjects with non-sarcopenic obesity, the primary objective of this study is to examine the consistency of the proposed diagnostic criteria with respect to circulating biomarkers and functional outcomes. secondary objectives include the assessment of additional variables and the detailed profiling of so subjects through questionnaires and multidimensional tests. the ethical aspect of the present study will be guaranteed through written informed consent and protection of privacy, respecting international regulatory standards. the investigators believe that this work provides significant contributions to the understanding of sarcopenic obesity and to the validation of diagnostic criteria, with possible implications for public health. the investigators are available for further clarifications and approvals required by the ethics committee.


Eligibility criteria:
inclusion criteria: * bmi equal more than 30 * caucasians exclusion criteria: * any disease or medication that can significantly affect body composition (eg.malignant diseases in the last 5 years, autoimmune diseases, neurological diseases, syndromic obesity), * level of physical activity more than 3 mets * alcohol intake more than 140g/wk for m and 70g/wk for f * participation in a weight-reducing program (last 3 months), * impossibility to perform dxa exam * pregnancy and breast-feeding.

Keywords: sarcopenic obesity obesity nutrition gut microbiome diagnostic ciriteria
specified drug-use survey of leuprorelin acetate injection kit 11.25 mg "all-case investigation: spinal and bulbar muscular atrophy (sbma)"

Conditions: Spinal and Bulbar Muscular Atrophy

Summary: the purpose of this survey is to evaluate the long-term safety and efficacy of leuprorelin acetate injection kit 11.25 mg in patients with spinal and bulbar muscular atrophy (sbma) in the routine clinical setting.

the drug being tested in this survey is called leuprorelin acetate injection kit 11.25 mg. this injection kit is being tested to treat people who have sbma. this survey is an observational (non-interventional) study and will look at the long-term safety and efficacy of the leuprorelin acetate injection kit 11.25 mg in the routine clinical setting. the planned number of observed patients will be approximately 300. this multi-center observational trial will be conducted in japan.

Eligibility criteria:
inclusion criteria: * all sbma patients who have been confirmed as receiving the drug exclusion criteria: * none
a study evaluating the efficacy and safety of pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma

Summary: the main purpose of this study is to assess the efficacy and safety of 3 dose levels of pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), who have received 1-3 lines of treatment including a covalent bruton tyrosine kinase (btk) inhibitor. the study is expected to last approximately 3 years.


Eligibility criteria:
inclusion criteria: * have confirmed diagnosis of cll/sll as defined by these iwcll 2018 criteria. * have received prior cll/sll treatment * have received at least 1, but not more than 3 lines of prior treatment for cll/sll * have received a covalent btk inhibitor * have a requirement for therapy consistent with iwcll 2018 criteria for initiation of therapy * capable of swallowing oral study medication. * have an eastern cooperative oncology group performance status (ecog) score of 0 to 2. exclusion criteria: * have received prior treatment with a btk degrader and a noncovalent btk inhibitor * have a history of greater than or equal to (\>=) grade 3 bleeding due to treatment with a btk inhibitor * have known or suspected richter's transformation * have known or suspected history of central nervous system involvement by cll/sll * previous or concurrent cancer distinct from cll/sll within 3 years before randomization. exceptions may occur with documented sponsor approval. examples include: * nonmelanoma skin cancer or lentigo maligna melanoma * cervical carcinoma in situ * localized prostate cancer undergoing active surveillance, and * localized (for example, lymph node negative) breast cancer with no evidence of active disease present for more than 3 years. individual may be receiving adjuvant hormonal therapy
using "pet response criteria in solid tumors (percist)" in evaluating response to neoadjuvant chemoradiotherpy for esophageal cancer

Conditions: Esophageal Cancer

Summary: this study is aimed to evaluate the effectiveness of 18f-fdg pet in the initial staging, therapy planning, and therapeutic response monitoring for esophageal cancer patients. purpose: 1. the incremental staging information by using 18f-fdg pet 2. the impact of the pet results on the patients' subsequent therapy planning 3. to compare treatment response using recist criteria and fdg pet results.

background: esophageal cancer is one of the leading malignancies in taiwan. accuracy tumor staging can direct to appropriate therapy planning and provide prognostic implications. positron emission tomography (pet) with \[18f\]-fluoro-2-deoxy-d-glucose (fdg) has been shown to have better n staging and prognostic stratification abilities than conventional imaging modalities, such as endoscopic ultrasonography (eus) and ct. purpose: this study is aimed to evaluate the effectiveness of 18f-fdg pet in the initial staging, therapy planning, and therapeutic response monitoring for esophageal cancer patients. method: patients with pathological proven esophageal cancer, age 20-90 year-old, will be included in this study. each patient will receive a baseline pet study. for those patients who received pre-operative ccrt, another pet will be performed 1-4 weeks after completion of ccrt. primary outcome: 1. the incremental staging information by using 18f-fdg pet 2. the impact of the pet results on the patients' subsequent therapy planning 3. to compare treatment response using recist criteria and fdg pet results. secondary outcome: to correlate the pet response rate and the patients' disease free survival and overall survival.

Eligibility criteria:
inclusion criteria: 1. age：20-90 years old 2. histological proved esophageal cancer 3. ecog performance status 0-2 4. written informed consent signed exclusion criteria: 1. prior chemotherapy or treatment for other systemic anti-cancer agent(s) 2. pregnant or intend to be pregnant 3. other malignancies known 4. other concurrent cancer treatment

Keywords: esophageal cancer 18f-fdg pet staging therapy planning therapy response monitoring prognosis
thromboelastography (teg) in the intrauterine growth restriction (iugr) neonatal population by gestational age

Conditions: Intrauterine Growth Restriction

Summary: the investigators aim to improve the understanding of teg in this population in an effort to improve outcomes in a population at high risk in both the presence and absence of blood product transfusions.

the investigators plan to 1.) examine dynamic hemostasis as measured by teg in the intrauterine growth restriction (iugr) neonatal population due to a high risk of requiring blood transfusions, 2.) determine the influence of gestational age on teg in this population, and 3.) examine the utility of teg as a tool for identifying coagulopathy in iugr neonates. the investigators hypothesize that thromboelastography parameters will change with gestational age in the iugr population in a manner similar to non-iugr populations and that neonatal comorbidities, maternal factors, and socioeconomic status will influence teg values; teg is likely a useful marker of dynamic hemostasis in this neonatal subpopulation.

Eligibility criteria:
inclusion criteria: participants included for medical record data and blood sample collection will be: * neonates diagnosed with intrauterine growth restriction, defined as a weight below the estimated 10th percentile and accordingly identified as such in any peripartum evaluation and * may have additional comorbidities and * full term iugr neonates will be have a gestational age of 37 weeks or greater or * preterm iugr neonates will have a gestational age less than 37 weeks or * preterm iugr neonates will have a gestational age less than 37 weeks participants included for medical record review data collection only will be: mothers of eligible neonates exclusion criteria: * constitutionally (familial) low birth weight, i.e. small for gestational age, babies or * born to women with life threatening coexisting morbidities (this may include severe pre-eclampsia, diabetes or suspected infections including hiv or herpes) or * neonates with an abnormal delivery or perinatal course including: fetal demise, death in the first week after birth, neonatal encephalopathy, meconium aspiration, and physical birth injuries (fractures and brachial plexus injuries)

Keywords: thromboelastography intrauterine growth restriction neonate gestational age hemostasis coagulopathy
pain response to cannabidiol in opioid-induced hyperalgesia, acute nociceptive pain and allodynia by using a model mimicking acute pain in healthy adults

Conditions: Acute Nociceptive Pain; Hyperalgesia; Allodynia; Opioid-induced Hyperalgesia

Summary: prospective, randomized, placebo-controlled, double-blinded, crossover study to investigate the effect of cannabidiol (cbd) on remifentanil-induced hyperalgesia in healthy volunteers in a well-established acute pain model. participants are randomized according to the order of the two treatments (cbd + remifentanil or placebo + remifentanil).

opioid-induced hyperalgesia (oih) is a clinically often neglected, but well described phenomenon. oih could also be shown for remifentanil in an acute pain model. as cbd showed antihyperalgesic potential in the animal model, this brings up the question if cbd might be used to prevent or diminish oih. until today there are no studies investigating cbd as an adjunct to remifentanil or other opioids regarding the oih. this is however of great clinical value because cbd with its possible antihyperalgesic effect on the oih might be a worthful adjunct for opioid based anaesthesia and analgesia. every participant will pass through two interventions with electrically induced pain (koppert model). cbd will be applied orally at the beginning of the intervention. pain, allodynia and hyperalgesia will be assessed and recorded every 10 min during the remifentanil infusion and afterwards.

Eligibility criteria:
inclusion criteria: * bmi between 18.5 until 25 kg/m2 * able to give informed consent exclusion criteria: * regular consumption of cannabinoids or other drugs / substances * regular intake of medications potentially interfering with pain sensation (analgesics, antihistamines, calcium and potassium channel blockers, serotonin / noradrenaline reuptake inhibitors, corticosteroids) * neuropathy * chronic pain * neuromuscular disease * psychiatric disease * known or suspected kidney or liver disease * pregnancy (cf. 8.6 trial specific preventive measures) / lactation * allergy / hypersensitivity to cannabidiol * contraindications for remifentanil (e.g. hypersensitivity)

Keywords: cannabidiol remifentanil